A detailed history of Mitchell Mcleod Pugh & Williams Inc transactions in Novartis Ag stock. As of the latest transaction made, Mitchell Mcleod Pugh & Williams Inc holds 5,979 shares of NVS stock, worth $623,490. This represents 0.14% of its overall portfolio holdings.

Number of Shares
5,979
Previous 5,954 0.42%
Holding current value
$623,490
Previous $633,000 8.53%
% of portfolio
0.14%
Previous 0.15%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$106.13 - $120.89 $2,653 - $3,022
25 Added 0.42%
5,979 $687,000
Q3 2023

Oct 20, 2023

BUY
$94.73 - $105.13 $28,419 - $31,539
300 Added 5.31%
5,954 $606,000
Q1 2023

May 10, 2023

SELL
$80.03 - $92.81 $2,000 - $2,320
-25 Reduced 0.44%
5,654 $520,000
Q4 2022

Feb 03, 2023

SELL
$75.55 - $92.52 $20,096 - $24,610
-266 Reduced 4.47%
5,679 $515,000
Q3 2022

Nov 07, 2022

BUY
$74.61 - $87.26 $40,364 - $47,207
541 Added 10.01%
5,945 $452,000
Q2 2022

Nov 18, 2022

SELL
$80.52 - $93.75 $43,561 - $50,718
-541 Reduced 9.1%
5,404 $457,000
Q1 2022

Apr 26, 2022

BUY
$80.11 - $90.62 $20,828 - $23,561
260 Added 5.05%
5,404 $474,000
Q2 2020

Jul 17, 2020

BUY
$80.93 - $91.1 $90,641 - $102,032
1,120 Added 27.83%
5,144 $449,000
Q1 2020

Apr 08, 2020

BUY
$70.67 - $99.01 $22,614 - $31,683
320 Added 8.64%
4,024 $332,000
Q2 2019

Jul 09, 2019

SELL
$75.4 - $92.8 $18,925 - $23,292
-251 Reduced 6.35%
3,704 $338,000
Q1 2019

Apr 11, 2019

BUY
$75.32 - $86.15 $85,186 - $97,435
1,131 Added 40.05%
3,955 $380,000
Q4 2018

Jan 10, 2019

BUY
$73.66 - $82.02 $8,102 - $9,022
110 Added 4.05%
2,824 $242,000
Q3 2017

Oct 12, 2017

BUY
$74.14 - $77.27 $201,215 - $209,710
2,714
2,714 $233,000

Others Institutions Holding NVS

About NOVARTIS AG


  • Ticker NVS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,151,000,064
  • Market Cap $224B
  • Description
  • Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...
More about NVS
Track This Portfolio

Track Mitchell Mcleod Pugh & Williams Inc Portfolio

Follow Mitchell Mcleod Pugh & Williams Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitchell Mcleod Pugh & Williams Inc, based on Form 13F filings with the SEC.

News

Stay updated on Mitchell Mcleod Pugh & Williams Inc with notifications on news.